Product
Imatinib/Nilotinib
1 clinical trial
1 indication
Indication
Chronic Myeloid LeukemiaClinical trial
Tyrosine Kinase Inhibitors of BCR/ABL: Pharmacokinetic and Pharmacogenetic Study in Patients Affected by Chronic Myeloid Leukemia. Evaluation of Efficacy and TolerabilityStatus: Recruiting, Estimated PCD: 2024-12-31